Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT) header
Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT) profile picture

Grateful for U S govt: rebalance p vote. Dept of defense; worked at Bell system 10 years, married to Telco engineer x 37 years. Nurse/research/metabolism focus.

TELEMEDICINE PROFESSIONAL
Joined January 2017
Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)Photo by Eve Fain, BSN MPH RN CDE, CHES (@espacetimeNOT)
Eve Fain, BSN MPH RN CDE, CHES retweeted
A new @UNEP /@WHO report makes the science clear: endocrine-disrupting chemicals are a global threat to health and the environment, and the evidence is strong enough to act now. Four Endocrine Society members helped lead this report. bit.ly/4zTJW7O #EDCs #Endocrinology
3
3
302
Eve Fain, BSN MPH RN CDE, CHES retweeted
Replying to @AnnieAndrewsMD
If you’ve never worked on a measles ward and watched 3 infants die on the same morning from acute respiratory failure secondary to MEASLES - don’t tell me I’m overreacting to RFKj’s insanity. It WILL happen here in the US.
18
181
3
2,399
42,005
Eve Fain, BSN MPH RN CDE, CHES retweeted
In this study, long-term air pollution exposure was consistently associated with higher HbA1c, reduced whole-body insulin sensitivity, secretion and clearance, and an increased burden of diabetes-related comorbidities in individuals type 2 diabetes.
2
4
1
15
708
Eve Fain, BSN MPH RN CDE, CHES retweeted
Two more kids died of measles this past week. For those keeping track, that’s the equivalent of more than 20 years’ worth of measles deaths during a period when vaccination rates were high enough to keep measles largely under control. This is what losing herd immunity looks like.
404
21
13
79
30,733
Eve Fain, BSN MPH RN CDE, CHES retweeted
👇
Q: Is the ground stop AI-related? Markwayne Mullin: We call it SI around here
1
2
1,065
Eve Fain, BSN MPH RN CDE, CHES retweeted
This narrative review summarizes the current available evidence on prebiotic intake in athletic populations, including effects on gastrointestinal structure and function, immune responses, recovery, sleep, wellness, mood and exercise performance.
1
3
17
636
Eve Fain, BSN MPH RN CDE, CHES retweeted
NEW @atherosociety CONSENSUS on HYPERTRIGLICERIDEMIA 🫀CV risk assessment as 1st step 👉🏻150-499 mg/dl: if a drug is needed, icosapent ethyl 1st choice 👉🏻>500 mg/dl plozasiran/olezarsen Last alternative: fibrates/omega3 nature.com/articles/s41569-0… #ipe #plozasiran #olezarsen
96
2
266
14,364
Eve Fain, BSN MPH RN CDE, CHES retweeted
Eating vegetables is very helpful for the vast majority of people. However, benefits' claims should be assessed objectively especially when we talk about impact on diabetes, fitness and physical health. Very small number of participants. @stevenmorris20 theguardian.com/society/2026…
1
1
325
Eve Fain, BSN MPH RN CDE, CHES retweeted
Replying to @drmarkhyman
You don't necessarily have to lift "heavy" to derive cognitive benefits. The bigger key appears to be the intensity of effort exerted. When training close to failure, light load resistance training has beneficial effects on cognitive health (e.g., doi.org/10.36950/2026.2ciss0…). This is particularly important for older adults, who often have joint-related conditions (e.g., osteoarthritis) that limit/prohibit their ability to train with heavy loads.
6
6
71
2,579
Eve Fain, BSN MPH RN CDE, CHES retweeted
AI Seinfeld goes to the DSA convention 🤣
520
4,733
660
24,668
3,769,534
Eve Fain, BSN MPH RN CDE, CHES retweeted
🇳🇴 A small Norwegian observational study (n=59) found 19 more min/day of moderate-to-vigorous physical activity on sports after-school days vs going home No significant difference vs regular after-school care Associations, not causation 🤸Play matters! fysioterapeuten.no/barn-fagf…
1
2
8
837
Eve Fain, BSN MPH RN CDE, CHES retweeted
In one of the first ObesityWeek related data release, CagriSema demonstrates ~21% average weight loss on lower doses in the REDEFINE 9 trial. This demonstrates clinically transformative degrees of weight loss can be achieved with even less than half the maximum dose. CagriSema 1.0/1.0 mg produced 20.7% weight loss at 68 weeks. novonordisk.com/content/nnco…
3
6
19
2,225
Eve Fain, BSN MPH RN CDE, CHES retweeted
An excellent and thought provoking article in @NatureMedicine by my friend and colleague, @JVLazarus. The liver is an early warning system for metabolic dysfunction, yet too often we wait until patients develop advanced liver disease or serious cardiometabolic complications before taking action. With better diagnostic tools and increasingly effective treatments, we have an opportunity to shift from treating advanced disease to early identification, prevention, and intervention. Congratulations to Jeff on this important call to action! #MASLD #MASH nature.com/articles/s41591-0…
1
38
1
83
3,952
Eve Fain, BSN MPH RN CDE, CHES retweeted
Our review is out in @TrendsImmuno: how gut microbial metabolites rewire immune cell energy metabolism in #IBD, and why it matters for therapy. Bonus: co-first author Qing Li also designed the cover 🧙 (the wizard and I share a first name, nothing more) doi.org/10.1016/j.it.2026.06…
1
7
42
1,540
Eve Fain, BSN MPH RN CDE, CHES retweeted
I suspect most/all VA hospitals not attached to civilian academic medical centers are the same.
2
33
Twin studies say Alzheimer's is 60 to 80% heritable. Common DNA variants were only explaining about 5% of it. A new Nature study of 2.8 million people puts that figure at 16%. That gap has bothered geneticists for years. Some argued there was little genetic risk left to find beyond APOE, the best-known Alzheimer's gene. Others argued over 1,000 variants must be involved. This paper tests which camp was right. Here is what the researchers did. The Psychiatric Genomics Consortium Alzheimer's group pooled 30 cohorts. That included 109,479 people with Alzheimer's, 74,141 proxy cases, and about 2.6 million controls. Proxy cases are people who don't have the disease themselves but reported that a parent did. Each parent shares half your DNA, so you can use their diagnosis as a stand-in. This matters because Alzheimer's strikes late, and most biobank volunteers are still too young to have it. The study is a genome-wide association study (GWAS). It scans millions of common DNA spelling differences and asks which ones show up more often in people with the disease. Each hit marks a region of the genome, called a locus, that nudges risk up or down. Sample ancestry was 91% European, 5% African, 3% East Asian, and under 1% each admixed American and South Asian. What they found: • 127 risk loci in total, and 48 of them are new • A heritability estimate of 16% with a newer statistical method, versus 6% with the older standard method on the same data • A polygenic score (a single risk number built from thousands of variants) that explained an average of 12.8% of risk variation in European cohorts, and up to 16.9% in the best one • In people over 65, the top 10% of the score had a sevenfold higher Alzheimer's prevalence than the bottom 10%, and a threefold higher prevalence than the whole sample • Alzheimer's-linked genes that were more active in microglia (the brain's immune cells) in patients, with microglia the only cell type that held up after correction (P = 1.58 × 10^-6) • 17 of the new genes already interact with approved drugs for other conditions, though only five had been tested as Alzheimer's targets Why did the old estimate come in so low? Heritability is the share of differences in risk between people that comes from their DNA. The older standard way to estimate it from GWAS data is called linkage disequilibrium score regression, or LDSC. It works by checking how strongly each variant's signal tracks with its neighbors on the genome, and it assumes risk comes from thousands of variants, each with a tiny and similar effect. Alzheimer's doesn't look like that. One variant, APOE-ε4, explains about 6% on its own. Think of it like estimating a choir's volume by assuming every singer is equally quiet. A single soloist breaks the assumption, and the total comes out too low. The authors tested this directly. They simulated a trait with an Alzheimer's-like architecture in UK Biobank genotypes, with one large-effect variant plus 1,000 small ones. LDSC underestimated the true heritability. The newer method (SBayesRC), which allows for a mix of big and small effects, recovered it once the APOE region was handled separately. A second check points the same way. The polygenic score explained more variance (about 13%) than LDSC said was theoretically possible for all common variants combined. So what do the new genes tell us about biology? The paper's logic runs in three steps. First, they matched each locus to its most likely gene. They combined machine learning predictions, links between DNA variants and gene activity, and earlier exome studies. Second, they asked which brain cell types use those genes most. Microglia kept coming up. Genes turned up in microglia in patients were enriched for genetic risk. Genes turned down in certain neurons were too, though that neuron signal weakened to nominal after correcting for general neuronal downregulation. The authors say it may not be specific. Third, they grouped genes by pathway. Immune activation, lipid binding, amyloid breakdown, and cell adhesion returned, as in earlier studies. Five processes were new to GWAS, including glutathione metabolism (oxidative stress handling) and sphingolipid metabolism (fats that shape cell membranes). A few genes stood out as drug candidates. SYK and AXL help microglia respond to amyloid. QPCT makes the exact amyloid modification that donanemab, an approved antibody, targets. Eight of the 48 new loci couldn't be tied to any known pathway, which hints at biology nobody has described yet. Now the limits. The data are 91% European. APOE-ε4 effect sizes ranged from an odds ratio of 1.7 in African ancestry to 3.4 in East Asian ancestry. But even European cohorts varied a lot, so cohort differences may explain much of that spread. The polygenic score also performed worse outside European ancestry, so it can't yet be applied evenly across populations. The 16% figure assumes a 5% lifetime prevalence. Assuming 20%, which is closer to the rate in people over 84, it rises to roughly 25%. The number depends on that choice. Proxy cases make up 40% of all cases, and parent reports can be wrong. The authors report that proxy and clinical results agreed closely (genetic correlation 0.99), but diagnosis accuracy is a real caveat. These are associations. A locus points to a region, and the gene assignment is a prediction. The drug target list is a hypothesis list, and two of the five tested targets failed in earlier human or mouse work. Finally, the polygenic score isn't a diagnostic. It shifts group-level risk. Most new variants change odds by only a few percent each. Prediction at the individual level is still limited. What does this mean for you? If you have a family history, your risk is genuinely shaped by DNA, and more of it is common variation than people thought. But common variants are not destiny. Each one nudges risk slightly, and none replaces the lifestyle and vascular factors that also matter. For the field, the finding that microglia keep appearing is a push to look beyond amyloid removal, which has delivered limited symptom relief so far.
26